Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Additionally we are shipping DCK Proteins (16) and DCK Kits (15) and many more products for this protein.
Showing 10 out of 138 products:
Human Polyclonal DCK Primary Antibody for IF, IHC (p) - ABIN391125
Hartford, Duan, Delaney, Mi, Kistner, Lamba, Huang, Dolan: Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. in Blood 2009
Show all 3 Pubmed References
Human Polyclonal DCK Primary Antibody for IHC - ABIN965975
Krawiec, Kierdaszuk, Shugar: Inorganic tripolyphosphate (PPP(i)) as a phosphate donor for human deoxyribonucleoside kinases. in Biochemical and biophysical research communications 2003
Show all 4 Pubmed References
Cow (Bovine) Polyclonal DCK Primary Antibody for WB - ABIN2784622
Iyidogan, Lutz: Systematic exploration of active site mutations on human deoxycytidine kinase substrate specificity. in Biochemistry 2008
Show all 2 Pubmed References
Human Monoclonal DCK Primary Antibody for ELISA, WB - ABIN514896
Funel, Giovannetti, Del Chiaro, Mey, Pollina, Nannizzi, Boggi, Ricciardi, Del Tacca, Bevilacqua, Mosca, Danesi, Campani: Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. in Laboratory investigation; a journal of technical methods and pathology 2008
Human Monoclonal DCK Primary Antibody for IF, ELISA - ABIN514902
Costantino, Witkiewicz, Kuwano, Cozzitorto, Kennedy, Dasgupta, Keen, Yeo, Gorospe, Brody: The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. in Cancer research 2009
Phosphorylated and activated DCK can inhibit radiation-induced cell death including apoptosis and mitotic catastrophe, and promote radiation-induced autophagy through PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies)/mTOR (show FRAP1 Antibodies) pathway.
Low deoxycytidine kinase expression is associated with periampullary adenocarcinoma.
recently described a human deoxycytidine kinase mutant (G12 (show TCF3 Antibodies)) that sensitizes cancer cell lines to treatment with gemcitabine. Here, starting from the G12 (show TCF3 Antibodies) variant, we identified a mutant that triggers even greater sensitisation to gemcitabine than G12 (show TCF3 Antibodies).
RNA expression of deoxycytidine kinase (DCK), human equilibrative nucleoside transporter-1 (ENT1 (show SLC29A1 Antibodies)) and ribonucleotide reductase M1 (RRM1 (show RRM1 Antibodies)) were significantly higher and cytidine deaminase (CDA (show CDA Antibodies)) was significantly lower in ex vivo Ara (show FOXC1 Antibodies)-C sensitive samples.
n the multivariate Cox (show COX8A Antibodies) regression analysis, we found that age at diagnosis, wild-type genotype of the CDA (show CDA Antibodies) A79C polymorphism, and wild-type genotype of the dCK C360G polymorphism were the most significant prognostic factors for predicting the risk of death
results strongly suggest that (1) the E197K alteration in DCK causes inactivation of DCK, and that (2) loss of the normal E197 allele is the crucial mechanism in acquisition of gemcitabine resistance in the RMKN28 tumor cell line
DCK rs12648166 and DCK rs4694362 SNPs were associated with hematologic toxicity (OR = 2.63, CI 95% = 1.37-5.04, P = 0.0036 and OR = 2.53, CI 95% = 1.34-4.80, P = 0.0044, respectively).
These findings indicate that the decitabine metabolic pathway affects its therapeutic effects, lower hENT1 expression may induce primary resistance and down-regulated DCK expression may be related to secondary resistance.
DCK expression levels are prognostic and had predictive value for sensitivity to 5-FU in pancreatic cancer.
DCK could regulate the migration and invasion of fibroblast-like synoviocytes through AKT (show AKT1 Antibodies) pathway in rheumatoid arthritis patients.
Mutation of a single serine 74 residue has profound effects on murine T and B lymphocyte (show AKAP17A Antibodies) development, suggesting that post-translational regulation of dCK has a role in maintaining genomic stability during hematopoiesis.
activating the dAdo-DCK-dATP pathway directly results in increased apoptosis in the lungs of mice with air-space enlargement and suggests a novel therapeutic target for the treatment of COPD (show ARCN1 Antibodies)
Deoxycytidine kinase is a new regulator of hematopoietic integrity and lymphocyte quiescence and survival.
The severe impact of dCK inactivation on lymphopoiesis was unexpected given that nucleoside salvage has been thought to play a limited, "fine-tuning" role in regulating deoxyribonucleotide triphosphate pools produced by the de novo pathway.
Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity.
, deoxycytidine kinase
, deoxynucleoside kinase
, deoxycytidine kinase 1
, deoxyribonucleoside kinase